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Summary
The influence of heparin on prothrombin conversion in plasma
was estimated by measuring prothrombin disappearance with the
aid of staphylocoagulase or by calculation from the thrombin
generation curve, compensating for simultaneous thrombin inacti-
vation by plasma protease inhibitors. In thromboplastin-activated
plasma the effect of heparin on prothrombinase (factor Xo-
factor Vu-phospholipid) is negligible compared to that on throm-
bin probably because both the extrinsic factor X activating
complex and phospholipid bound factor Xo are insensitive to
AT Ill-heparin action. In contact-activated plasma prothrombin-
ase generation is inhibited by heparin, becaùse heparin lowers the
ambient concentrations of thrombin so that the feedback activa-
tion of factor VIII by thrombin is diminished. Consequently, the
delayed factor Xu generation causes a lag phase in prothrombin-
ase generation. We conclude that heparin in plasma acts by its
thrombin scavenging properties. No direct action on prothrom-
binase or on the factor X activating enzyme needs to be assumed
if one tâkes into account the effect of thrombin depletion on
thrombin-mediated feedback reactions.
lntroduction
The anticoagulant effect of heparin is considered to be
primarily due to the stimulating action of this drug on the
inactivation of clotting proteases by antithrombin III (AT III). It
has been demonstrated that the activated forms of the factors II,
IX, X, XI and XII as well as kallikrein are susceptible to this
action (see Ref.1 for a review). No consensus has as yet been
obtained on the question of which of the various possible
inactivations are instrumental in causing the effect of heparin on
the clotting of plasma.
Data on the decay of activated clotting factors added to plasma
and on the influence of heparin on this process are readily and
frequently obtained (1). However, for two reasons they cannot be
used to judge the situation in clotting plasma. In the first place it
has been found that the kinetics of inhibition of thrombin and
factor Xo generated endogenously in plasma is different from
those of puri f ied proteases added to plasma (2-4).
In the second place, it should be recognized that for coagula-
tion proteases to be generated at a significant rate, multimolecu-
lar complexes, consisting of a converting enzyme, a cofactor and a
procoagulant surface, have to be formed (5). The converting
enzyme, factor Xu for example, in this complex is heavily
protected from inhibition by AT Ill/heparin (6-9)
The question of the mode of action of heparin in plasma has
gained importance with the advent of low molecular weight
* Part of this work has been presented at the XIth International
Society of Thrombosis and Haemostasis Congress, Brussels, 1987.
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heparins. It has been hypothesized that the antithrombotic
properties of a heparin are related to its anti-factor Xu activity,
rvhereas bleeding would correlate to antithrombin action (10). In
this context it is tacitly assumed that classical heparin which
undoubtedly has antithrombotic properties, does act on factor Xu
in vivo. Today, this relationship is seriously questioned (ll, 12).
In the present study we report on the effects of heparin on the
generation and inhibition of the prothrombin converting, i.e.
prothrombinase, activity ip clotting plasma. Determination of
prothrombinase activity requires the estimation of the rate of
prothrombin conversion, which can be obtained by immunologi-
cal determination of activation peptides (13) or by following the
breakdown of labelled prothrombin (14, 15). Both methods are
valid but set practical limits to the number of samples that can be
handled and therefore do not allow estimation of the precise time
course of prothrombinase activity.
Alternatively, one can study factor X activation but this
requires the absence of prothrombin because artefacts due to
thrombin generation have to be avoided (a). In prothrombin
depleted plasma, however, effects of heparin on the thrombin-
calalyzed activation of factor V and VIII are missed.
We therefore developed methods based on mathematical
analysis of the thrombin generation curve in defibrinated plasma
and on measurement of prothrombin consumption with the aid of
staphylocoagulase (2). Part of the results obtained have been
presented at the XIth ISTH Congress in Brussels 1987 (16).
Materials and Methods
Materials
The chromogenic substrate for thrombin was H.D-Phe-Pip-Arg-pNA
(52238) from Kabi, Sweden. Kaolin was "Kaolin léger" provided by
B.L B Laboratoires du Bois de Boulogne (Puteaux, France). The 4th
International Standard for Heparin (19a U/mg) was from the National
Institute for Biological Standards and Control. The phospholipid vesicle
preparation contained 20% phosphatidylserine and 80% phosphatidyl-
choline and was prepared as described previously (17).
Plasmas
Blood from healthy donors was collected on 0.13 M trisodium citrate;
nine parts of blood to one part of citrate solution A first and a second
centrifugation were performed at 3,000 x g, at 15' C for 15 min. A third
centrifugation was done at 4" C, for 1,hour at23,000 x g. The platelet
free plasma thus obtained was stored at -80" C. It was checked that the
clotting factors and the antiproteases were in the normal range (18).
Defibrinated plasma was obtained by mixing an aliquot of plasma with
1 :50 volume of a reptilase solution, letting a clot form for 10 min at37" C
and keeping the clotted plasma at 0" C for 10 min The fibrin formed was
discarded by centrifugation (10 min, 5,000 x C, 4" C) or by winding it on
a small plastic spatula. The concentrations of factors II, Y VII, VIII, lX,
X, XI, and XII did not significantly change by the reptilase treatment as
has been shown before (2).
Proteins
Human brain thromboplastin was prepared as described in (19). It was
homogenized in a Potter Elvehjem homogeniser for 3 min, centrifugated
at 2,000 x g for 15 min and stored at -20" C in 0.1 ml aliquots. Before
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use it was thawed, diluted with 0.05 M lris-HCl pH 7.35 containing
100 mM of CaC12, so as to obtain a clotting time of 90 sec when incubated
with normal non-defibrinated plasma under the same conditions as used
for the thrombin generation experiments. The dilution required was 1:40
for the batch of thromboplastin used here and between 1:30 and 1:50
with other batches. The diluted thromboplastin was incubated at37" Cfor
t hour and then kept at room temperature. In this way it remained stable
for at least 4 hours. Reptilase was obtained from Laboratoires Stago
(Asnières, France), a solution was obtained according to the instructions
of the manufacturer. Soybean trypsin inhibitor (batch no 43 F-800) was
obtained from Sigma (St Louis, USA) Staphylocoagulase, was prepared
as described in Hendrix et al. (20) or obtained from Laboratoires Stago
(Asnières, France) and prepared according to the instructions of the
manufacturer. Human a-thrombin was prepared according to Pletcher
and Nelsestuen (21), active site titrated and used for constructing a
standard curve. Factors V, V" and factor X" were obtained as described
by Lindhout et al. (22) Factor VIII was prepared according to Vehar and
Davie (23) with the modifications by van Dieijen et al. (24). Factor IX
was prepared according to Fujikawa et al. (25) and activated by
incubation with purified factor XI" (26).
Determination of Prothrombinase Activity in Plasma
To 200 pl of defibrinated plasma is added 50 pl of 0 05 M Tris-HCl,
0.1 M NaCl, 0 5 mg/ml ovalbumin, pH 7.35 containing heparin at the
desired concentration and incubated for 5 miî at 37' C' At zero time,
thrombin generation is started by the addition of 50 pl of a solution
containing 100 mM of CaCl, and a trigger of coagulation. For the extdnsic
system this is human brain thromboplastin diluted as described above
(final dilution 7:240), lor the intrinsic system 1 pM phospholipid and
0.25 mg kaolin (final concentrations). When other triggers are used they
are indicated in the legends. At intervals a 10 pl aliquot of the mixture is
sampled into a disposable plastic cuvette containing 0.465 pl of 0.05 M
Tris-HCl, 0.1 M NaCl, 20 mM EDTA, 0 5 mg ovalbumin/ml, pH 7.9 and
25 pl of 52238 (4 mM) prewarmed for at least 5 min at 37" C After
1.20 sec the reaction in the cuvette is stopped by adding 300 pl of
concentrated acetic acid. The cuvettes are read at 405 nm in a LKB
Ultrospec II spectrophotometer. The amidolytic activities in the plasma
samples were calculated from the O.D. readings and expressed as the
equivalent concentration of thrombin. The generation of prothrombinase
activity was calculated from the amidolytic activity curve with the aid of a
computer program as described previously (2). Briefly, the observed
amidolytic activity is the sum of thrombin activity and the activity of the
orM-thrombin complex The rate of thrombin generation at any moment
is the sum of two processes: a) the conversion of prothrombin into
thrombin by prothrombinase and b) the decay of thrombin by the action
of plasma protease inhibitors. The rate of inhibition of thrombin at any
moment can be calculated from the concenttation of thrombin at that time
and the pseudo first order rate constant of inhibition of thrombin by
antithrombin III (kr) and o2-macroglobulin (kr) The rate of prothrombin
activation (prothrombinase activity) than can be calculated from the
observed rate of generation of amidolytic activity and the rate of thrombin
inhibition.
In formula:
g (r) dr = A(t) + (kr + k2 - 1k2)e tkzt
t
I
0
A (r)  efkr 'dr  (1)
where g(t) : thrombin generation from prothrombin as a function of
time, A(c) : amidoiytic .activity found at time t, f : the ratio of the
enzymatic activity of 1 mole of o2M-thrombin over that of 1 mole of free
thrombin, kr : AT III dependent decay constant of thrombin in plasma,
k2 : o2M dependent decay constant of thrombin in plasma
Determination of the Pseudo First Order Rate Constant of Inhibition of
Thrombin in Plasma
Defibrinated plasma (200 pl) was incubated with 24 pl of buffer
containing 0.05 M Tiis-HCl, 0.1 M NaCl, 0.5 mg ovalbumin/ml, pH 7.35.
Thrombin generation was started as described in the previous section
Two minutes after the peak activity of thrombin, 10 pl of Soybean Tiypsin
Inhibitor (SBTI) solution (10 mg/ml) was added, together with 16 pl of
buffer that contained the heparin to be tested. SBTI at this concentration
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was shown to stop completely and instantaneously the activity of
prothrombinase and not to influence the activity of thrombin (2). At
suitable time intervals after addition of the SBTI solution, 10 pl aliquots
of the incubation mixture were added to cuvettes to measure residual
thrombin activity as described The pseudo first order rate constant of
inhibition of thrombin generated in plasma was calculated by fitting the
data to
C,: Cn * Coe-(kt + kz)t (2)
where C, is the thrombin activity at time t, Cq is the steady end-level
activity, Co + CR is the thrombin activity at the time of SBTI addition, k1
is the AT III-dependent decay constant of inhibition of thrombin, kr is the
decay constant of inhibition of thrombin by o2-macroglobulin (o2-M). The
parameters (C" + CR) and (kr + k2) are calculated by means of a least
squares fit of the model to the data, using the Box-Kanemasu modification
of Gauss' method (27)
We have shown before that the amounts of thrombin complexed with
o2M and AT III are proportional to the respective rate constants of
inhibition of thrombin. The amount of o2M-thrombin can be determined
directly from the residual thrombin activity, Cp, because o2M-thrombin
has under our experimental conditions an amidolytic activity of 56% of
that of free thrombin (2). The amount of AT Ill-thrombin can be
calculated from the amount of prothrombin consumed (P) and that is not
accounted for by otM-thrombin.
Thus.
k r / k ,  :  1 . 33  CR/ (P '  l . 88CR)  (3 )
The rate constants, k, and k2, then can be obtained from equations 2
and 3.
M easurement of Residual Prothrombin Concentration
The residual prothrombin concentration during thrombin generation in
plasma was estimated by taking samples (20 pl) at 1 min intervals and
incubation with 20 pl of 0.05 M Tiis-O 1 M NaCl-O.5 mg/ml ovalbumin,
pH 7.9 containing 20mM EDTA and ZUlml of heparin. In this way
thrombin in the plasma sample was inactivated aimost instantaneously. To
a 10 pl portion of this mixture 10 pl of a 2 pM staphylocoagulase solution
was added After 2 min incubation ar3'7" C the thrombin-like amidolytic
activity was measured. This activity (A) gives the amount of prothrombin,
because the prothrombin-staphylocoagulase (1 :1 mol/mol) complex has
the same molar activity towards S 2238 as thrombin and is not inactivated
by AT III/heparin (20), plus the amount of o2M-thrombin already present
in the sample Another portion of the incubation mixture, prior to the
addition of staphylocoagulase, was assayed for the amount of orM-
thrombin (B)
The residual prothrombin concentration at time t was calculated from
the difference between the activities prior and after the incubation with
staphylocoagulase (A,-B,) The rate of prothrombin consumption Vt,
during thrombin generation in plasma could then be calculated directly
from
V, :  [ (A,2-8,2)-(At ]  -Bt l ) l / ( t r - t l )
Results
In order to investigate the effect of heparin on prothrombinase
generation and inactivation in clotting plasma we used two
methods: i) an indirect method that calculated the prothrombin-
ase activity from the generation of thrombin like amidolytic
activity and ii) a direct measurement of residual prothrombin
levels.
In the following section we show that these methods give
comparable results. Because the indirect method is more precise
and quicker, the remainder of the experiments were performed by
this method.
Choice and Evaluation of the Method
Our method of calculating prothrombinase activity from
amidolytic activity curves requires pseudo first order reaction
t
I
0
kinetics between thrombin and its plasma inhibitors. This sim-
plifying assumption could be shown to be acceptable within the
limits of experimental error in the absence of heparin (2). It is
seen in Fig. 1 that the decay of thrombin in the presence of
heparin can not be distinguished from a logarithmic approach to a
steady end-level, indicating that the process can in good approxi-
mation be described as the sum of two pseudo first order
reactions, one inactivating thrombin completely (complexing by
AT III and thrombin inhibitors of minor importance) and the
other yielding a product with a persisting amidolytic activity (o2-
macroglobulin-thrombin complex).
This allowed us to calculate the time course of prothrombinase
activity in the presence of heparin. In order to validate the results
we compared them to prothrombin consumption velocities as
measured directly with the aid of staphylocoagulase as described
in Materials and Methods.
This procedure involves calculations on the differences
between large values. Even though the standard error of each of
the determinations can be reduced to 3-4'Â , the standard error of
the resulting prothrombin disappearance rate was calculated to be
between 9 andI5"Â.
From Fig.2 it can be seen that at two heparin concentrations
the rate of prothrombin activation as calculated from the throm-
bin generation curve coincided tolerably with the rate of pro-
thrombin activation as determined directly with the aid of
staphylocoagulase.
We conclude that our mathematical approach gives an accept-
able picture of the rate of prothrombin activation in the absence
as well as in the presence of heparin. We cannot .exclude the
possibility of a slight systematic overestimation of the velocities in
the descending limb of the curve. This does not, however,
influence the interpretation of the observations.
Effect of Heparin on the Decay of Thrombin Generated in Plasma
In order to compute the prothrombin conversion velocity, i. e.
prothrombinase activity, from thrombin generation curves at a
series of heparin concentrations it is necessary to determine the
breakdown constants of thrombin in plasma in the presence of
different concentrations of heparin. This was done as shown in
Fig. 1. At all heparin concentrations tested, curves were obtained
that showed a logarithmic approach to a final level. Data analysis
as described in Materials and Methods resulted in a pseudo first
order rate constant of inhibition of thrombin by o2-macroglobulin
of 0.232 + 0.004 (S. E. M.; n = 25) min 1, and was independent of
the heparin concentration. The antithrombin Ill-dependent rate
constant of inhibition of thrombin generated in plasma as a
function of the heparin concentration is depicted in Fig. 3.
Heparin and the Generation of Prothrombinase Activity in
Thromb op las tin- Activ ate d Plasma
We determined the course of the generation of thrombin like
amidolytic activity in plasma triggered by thromboplastin in the
presence of different concentrations of heparin. As expected
heparin had a clearcut reducing effect on thrombin yield (Fig.4).
From these curves we calculated the course of thrombin genera-
tion (i.e. the activity without the contribution of the o2M-
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Fig 1 Inactivation of thrombin, generated in thromboplastin-activated
plasma, in the presence and absence of heparin Defibrinated plasma was
incubated with thromboplastin (final dilution 1:240). After 5 min SBTI
was added and aliquots were taken to measure amidolytic thrombin
activity until a steady end-level, Cp, of residual thrombin activity, i.e
o2M-thrombin, was obtained (equation 2, Materials and Methods). The
vertical axis (log scale) represents the measured thrombin activity minus
C* The horizontal axis reprèsents the reaction time after the addition of
SBTI. Open symbols: no heparin added. Closed symbols: 0.1 U/ml of
heparin was added simultaneously with SBTI. The different symbols
replesent repeated runs of the experiment
,o
T i m e  ( m i n )
Fig.2 Generation of prothrombinase activity in thromboplastin-acti-
vated plasma. Defibrinated plasma was incubated with thromboplastin
(final dilution 1,:240) in the absence (O) or presence of 0.02 U/ml (Â) or
0.1 U/ml (O) of heparin as described in Materials and Methods. The
symbols represent the rate of prothrombin activation as calculated from
residual prothrombin concentrations using staphylocoagulase (see Mate-
rials and Methods for further details). The drawn lines join the rates of
prothrombin activation calculated from the thrombin generation curves
according to equation 1 (Materials and Methods) The error bars are
2  X  S . D .
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Flg 3 The AT Ill-dependent pseudo first oder rate constant of inhibi-
tion of thrombin generated in thromboplastin-activated plasma as a
function of the heparin concentration. The pseudo first order rate
constant, kr + k2, was obtained from a plot as shown in Fig. l The rate
constant of the AT Ill-dependent inactivation of thrombin, kt, was
obtained by assuming a rate constant of inhibition of thrombin by o2M, kr,
oT 0 232 min I (see text for further details)
thrombin complex) and the course of the prothrombinase activity
cun'es.  using the appropr iate rate constant  of  inhib i t ion endoge-
noush' senerated thrombin as shown in Fig. 3. The results of these
calculations are summarized in Fie 5.
200
0  5  1 0
T i m e  ( m i n )
Fig.4 The effects of heparin on the amidolytic activity generated in
plasma via the intrinsic and the extrinsic pathway The amidolytic activity
i. e. the activity of thrombin plus the or macroglobulin-thrombrn complex,
is expressed as the equivalent amount of thrombin. The curves were
obtained as described in Materials and Methods. No heparin: extrinsic
(O-a) intrinsic (O---O); 0.05 U/m1 heparin: extrinsic ( - )
intrinsic (A À); 0.1 U/ml heparin: extrinsic (O-O) intrinsic(o---o)
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The most intriguing feature is that the peak activity of
prothrombinase generation is hardly inhibited by concentrations
of heparin that have an important effect on the thrombin yield. In
the concentration range of 0.03-0.04 U/ml, heparin seems even
to have a slight enhancing effect on the peak prothrombinase
activity. On the other hand the velocity at which the prothrombin-
ase activity builds up is slightly slowed down (results not shown,
see ref. 16). At 0. 1 U/ml of heparin there is a definite inhibition of
both the initial rate of prothrombinase generation and peak
prothrombinase activity. The descending slopes of the prothrom-
binase activity generation curves are the result of prothrombin
deplet ion (2).
Heparin and the Generation of Prothrombinase Activity in
Contact-Activ ated P las ma
After the thromboplastin-induced thrombin generation, we
studied the intrinsic pathway as triggered by kaolin in the
presence of phospholipid. As shown in Fig. 4, an effect of heparin
could be observed, not only on the amount of thrombin generated
but also on the lag time of thrombin generation When we
calculated the effect of heparin on the time course of prothrombin
activation a significant inhibition of the prothrombinase genera-
tion was observed (Fig.5). In contrast to the situation in
thromboplastin-activated plasma, prothrombinase generation via
the intrinsic system seems to be inhibited by heparin even at low
0  0 . 0 s  0 . 1
H e p a r i n  ( u / m l )
Fig. 5 The inhibition of thrombin generation and prothrombinase gener-
ation by heparin With equation 1 the course of thrombin activity and
prothrombinase activity was calculated from data as in Fig.4. The
inhibition of the peak activities relative to an uninhibited control are
given. Inhibition of extrinsic thrombin generation (O-O), inhibition of
intrinsic prothrombinase generation (l-l); inhibition of extrinsic
prothrombinase generation Computed (O-O) and determined by the
staphylocoagulase method (I)
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concentrations. There is no reason to assume that the prothrom_
binase itself is different in the two cases, so it is likely that the
generation of factor Xu via the intrinsic pàthway is inhibited by
heparin.
In an attempt to differentiate between an effect on the factor X
activating complex itself (FVIII", FIX., phospholipid) and an
effect on the generation of the factor X activating complex
(factors VIII^ and IXu generation), we examined the effeci of
heparin on thrombin generation in plasma activatecl by a fully
assembled factor X converting complex that consisted of the
purified factors VIII^ and IXu, phospholipid and Ca2+. Thrombin
generation thus triggered was inhibited by heparin but the lag
time had disappeared (data not shown). Like in the case of thè
extrinsic pathway, the inhibition of thrombin generation must be
mainly attributed to the scavenging of thrombin, because when
the course of prothrombinase activity was calculated no inhibition
was seen at concentrations of up to 0.075 U/ml of heparin and
only 35"Â inhibition was caused by 0.1 U/ml of standard heparin.
From these results we concluded that it was likely that in the
case of kaolin activation, the formation of one of the protein
constituents of the intrinsic factor X activator is inhibiied by
heparin. We therefore added one or the other constituent in
preactivated form (Fig.6). When clotting is started by activated
factor IX and phospholipid, rhe inhibition by a heparin concen-
tration of 0 05 U/ml is overwhelminq. When activated factor VIII
is added to a plasma in which thrombin generation is started by
kaolin the inhibition of thrombin formation that was observed is
comparable to that seen in the extrinsic system and can be
explained by thrombin scavenging. Moreover, no lag phases were
observed. When the factor VIII used in this experiment was not
preactivated with thrombin, then the inhibition by heparin
reappeared, as did the lag phases.
We concluded that the presence of factor VIII. but not that of
factor IXu prevents the inhibition of intrinsic prothrombinase
generatlon.
Discussion
Ever since it has been reported that phospholipids and
factor Vu can protect factor Xu from the action of AT III
(-heparin) it has remained an open question what the importance
of this phenomenon is for the coagulation of plasma, especially in
the presence of heparin (6-9). It was our purpose to investigate to
what extent factor Xu and the factor X activating proteases are
inhibited by AT Ill(-heparin) during thrombin generation trig_
gered via the extrinsic and the intrinsic pathway in the complex
medium of whole plasma. This question iJ relevant to the probiem
of the mode of action of heparin in vivo. Any action that can be
demonstrated not to occur in plasma can hardly be expected to
contribute to the antithrombotic effect of heoarin.
In order to estimate lhe rate of prothrombin conversion as a
function of time, we used two independent methods i) direct
estimation of the level of residual prothrombin in the course of
time with the aid of staphylocoagulase and ii) indirect computa-
tion of the prothrombinase activity from the experimentally
observed rate of thrombin generation corrected for the simultane_
ous thrombin decay caused by AT Ill(-heparin) and other pro_
tease scavengers (2).
The two methods appear to give similar results both in the
absence and in the presence of heparin (Fig.2). The staphyloco_
agulase method is relatively cumbersome and, because the ve-
locities are calculated by subtraction of four activities, tends to
large experimental errors. We therefore used the indirect method
' in further experiments.
From Fig.3 it can be seen that in plasma between 0.005 and
0.010 U/ml of heparin, heparin seems to be neutralized probablv
5  1 0  1 5  2 0
T i m e  ( m i n )
Fig.6 'fhe effect ofheparin on kaolin- and factor IX"-induced amidolytic
activity in plasma. The amidolytic activity, i.e. the activity of thrombin
plus the a, macroglobulin-thrombin complex, is expressed as the equiva-
lent amount of thrombin. Defibrinated plasma was incubated with kaolin
(0.83 mg/ml), calcium (20 mM). phospholipid (1 prM) and factor VIIIa
(1 U/ml) in the absence (O) or presence (!) of 0.05 U/ml of heparin, or
defibrinated plasma was incubated with 2 nM factor IXu, 20 mM calcium,
1 pM phospholipid, either in the absence (O) or presence (I) of
0.05 U/ml of heparin
by high affinity binding to plasma proteins, other then AT III
(28-30). After compensating for this effect we found a linear
increase of the pseudo first order rate constant of inhibition of
thrombin generated in plasma with the heparin concentration of
8.6 min-l mg-l ml 1. This is considerably lower then was found in
purified systems (38.7 min 1 mg 1 ml-1, data not shown). At least
two phenomena may explain this difference: i) Heparin may bind
reversibly to various plasma proteins and thus, its effective
concentration may be lower than the amount added would
predict. ii) Thrombin generated in situ is less vulnerable to AT III
than exogenous thrombin is (2), as has also been demonstrated
for thrombin formed by prothrombinase from prothrombin in a
purified system (31).
From Fig. 4 tt can be seen that there are essential differences
between the effect of heparin on the intrinsic and the extrinsic
system. In the extrinsic system there is no lag phase either in the
presence or absence of heparin. In the intrinsic system there is a
lag phase, that is significantly increased by heparin.
The peak amount 
_of prothrombinase activity triggered by
thromboplastin and Ca2+ is not significantly inhibited by 0.075 U/
ml of heparin, a concentration that inhibits the net maximal
velocity of thrombin formation as much as 85%. This means that
the velocity of prothrombin conversion must be the same in the
presence and in the absence of heparin so that the inhibition of
the net generation of thrombin must be entirely contributed to the
increase of thrombin scavenging in the presence of heparin.
Heparin, at concentrations that do not reduce prothrombinase
generation induced via the extrinsic pathway, does inhibit the
development of prothrombinase activity when thrombin genera-
tion is triggered via the intrinsic system (Fig.5). This must be
caused by inhibition of the phospholipid-Ca2+-factor IXu-factor
VIII. complex itself or by inhibition of the generation of one of its
constrtuents. The generation of factor IXu has been demonstrated
not to be inhibited in plasma (32,33). Thus, either factor IXu is
scavenged and/or the generation of factor VIII" is inhibited bv
heparin. To distinguish between these possibilities we addeâ
either one or the other factor in its activated form from zero time,
while the other had to be generated during the process. A lag time
c
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is seen only when no factor VIII. is added to the mixture and then
the lag times increase with heparin concentration. The observed
lag phases probably represent the time necessary for a sufficient
amount of factor VIII to be activated.
Our main conclusion is that the inhibition by heparin of
prothrombinase gèneration is due to inhibition of the feedback
activation of factor VIII.
Our observation agree with the fact that the specific thrombin
inhibitor D-Phe-Pro-Arg-Chloromethylketone (PPACK) inhibits
prothrombin activation (14) and factor X activation via factor IXu
(15) and supports the explanation of this phenomenon by the
inhibition of feedback activation.
Our results also agree with the observations of Ofosu et al. (14)
who showed that the effective inhibition of the generation of
thrombin activity appears to require sulphated polysaccharides
which can potentiate the inactivation of thrombin. These authors
also report inhibition of prothrombinase by standard heparin in
antithrombin III depleted plasma and by heparin with a low
affinity to antithrombin III in normal plasma (34). However,
these effects are seen at heparin concentrations (0.2-3 U/ml) that
are appreciably higher then those used here.
The concentrations of heparin that we studied are relatively
low. We do think that they are relevant for the situation in
patients that receive heparin because such levels are routinely
encountered in low dose heparin treatment.
Our results explain a well known paradox from the clinical
laboratory. Although both the thrombin time and the activated
partial thromboplastin time (APTT) are sensitive to heparin, the
prothrombin time is not. When we carried out experiments with
non-defibrinated plasma it appeared that coagulation is always
seen at the start of the explosive formation of thrombin. The
APTT actually measures the lag time of thrombin formation in
the intrinsic system. This lag time is determined by the availability
of thrombin for the activation of factor VIII. The APTT
therefore, must be considered to be affected primarily by the
action of AT Ill/heparin on thrombin just like the thrombin time
15.
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